المؤلفون: Caroline Robert, Jacob Schachter, Thierry Lesimple, C. Dutriaux, Dirk Schadendorf, Monique Tan, Axel Hauschild, Georgina V. Long, R. Dummer, Eduard Gasal, Mario Santinami, Kohinoor Dasgupta, James Larkin, Mario Mandalà, Andrew M. Haydon, John M. Kirkwood, Vanna Chiarion Sileni, Laurent Mortier, Victoria Atkinson, Marta Nyakas, Ruth Plummer

المساهمون: University of Zurich

مصطلحات موضوعية: Male, Oncology, Skin Neoplasms, medicine.medical_treatment, Medizin, Administration, Oral, 2700 General Medicine, 030204 cardiovascular system & hematology, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Oximes, Medicine, 030212 general & internal medicine, Neoplasm Metastasis, Melanoma, Trametinib, Imidazoles, Follow up studies, 10177 Dermatology Clinic, General Medicine, Middle Aged, Female, Adjuvant, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Disease-Free Survival, 03 medical and health sciences, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Humans, Stage III melanoma, Protein Kinase Inhibitors, Survival analysis, Aged, Neoplasm Staging, business.industry, Dabrafenib, Survival Analysis, Clinical trial, Mutation, business, Follow-Up Studies

وصف الملف: 848_Dummer_R._et_al._Five-Year_Analysis_of_Adjuvant_Dabrafenib_plus_Trametinib_in_Stage_III_Melanoma_NEJM_2020.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d710d2b0f671e5dafc838391b9965d4aTest
https://www.zora.uzh.ch/id/eprint/190018Test

المؤلفون: Mohammed M. Milhem, Peter Mohr, Paul Nathan, Piotr Rutkowski, Anthony D'Amelio, Peter Hersey, Felix Kiecker, Jochen Utikal, Lev V. Demidov, Caroline Robert, Reinhard Dummer, Claus Garbe, Dirk Schadendorf, Jessica C. Hassel, Bijoyesh Mookerjee, James Larkin, Keith T. Flaherty

المساهمون: Department of Dermatology (CHU Besançon), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), N.N. Blokhin Russian Cancer Research Center, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Novartis Pharmaceutical Corporation, University of Zurich, Robert, Caroline

المصدر: European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 109, pp.61-69. ⟨10.1016/j.ejca.2018.12.015⟩

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Medizin, Phases of clinical research, Targeted therapy, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Melanoma, Trametinib, Aged, 80 and over, Brain Neoplasms, MEK inhibitor, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Prognosis, 3. Good health, Dacarbazine, Survival Rate, 030220 oncology & carcinogenesis, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Paclitaxel, Pyridones, 610 Medicine & health, Pyrimidinones, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Adverse effect, Aged, Chemotherapy, business.industry, 030104 developmental biology, Mutation, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28197cc98bbc5b4b985accfda8ddbdbdTest
https://pubmed.ncbi.nlm.nih.gov/30690294Test

المؤلفون: Christian U. Blank, Adil Daud, Rene Gonzalez, Kim Margolin, Scot Ebbinghaus, Ziwen Wei, Dirk Schadendorf, Antoni Ribas, Anna C. Pavlick, Lee D. Cranmer, Caroline Robert, April K.S. Salama, Jacob Schachter, Omid Hamid, Reinhard Dummer, Nageatte Ibrahim, F. Stephen Hodi, Igor Puzanov, Tara C. Gangadhar, Paolo A. Ascierto

المساهمون: University of Zurich, Hamid, Omid

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Phases of clinical research, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, 1306 Cancer Research, Melanoma, Aged, 80 and over, education.field_of_study, Cross-Over Studies, Drug Substitution, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Population, Ipilimumab, 610 Medicine & health, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, education, Protein Kinase Inhibitors, Aged, Chemotherapy, business.industry, medicine.disease, Confidence interval, Surgery, 030104 developmental biology, Drug Resistance, Neoplasm, Mutation, business

وصف الملف: 721_Hamid_O._et_al._Final_analysis_of_randomised_trial_comparing_pembrolizumab_versus_Eur_J_Cancer_2017.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab24a3779538f584d0432f320113cbb5Test
https://www.ncbi.nlm.nih.gov/pubmed/28961465Test

المؤلفون: Stéphan Vagner, Alexander M.M. Eggermont, Lise Boussemart, Yungan Tao, Laurence Vilcot, Pierre Blanchard, Caroline Robert, Brigitte Dréno, Barouyr Baroudjian, Frédéric Dhermain, Christine Mateus, Eric Deutsch, Emilie Routier

المصدر: European journal of dermatology : EJD. 24(2)

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Radiosensitizer, Pathology, medicine.medical_specialty, Radiation-Sensitizing Agents, Indoles, Skin Neoplasms, medicine.medical_treatment, Dermatology, Remission induction, medicine, Combined Modality Therapy, Humans, Vemurafenib, Melanoma, Aged, 80 and over, Sulfonamides, business.industry, Remission Induction, Antitumor response, medicine.disease, Clinical trial, Radiation therapy, Cancer research, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59d40e250153d141af1fea8d646604c0Test
https://pubmed.ncbi.nlm.nih.gov/24721778Test

المؤلفون: Eric Deutsch, Christine Mateus, Gorana Tomasic, Catherine Boivin, Caroline Robert, Yun Gan Tao, Emilie Routier, Joël Claveau, Lise Boussemart

المصدر: JAMA dermatology. 149(7)

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Radiosensitizer, medicine.medical_specialty, Indoles, Skin Neoplasms, medicine.medical_treatment, Folliculitis, Dermatology, Radiation Tolerance, medicine, Radiodermatitis, Humans, Vemurafenib, Adverse effect, Melanoma, Protein Kinase Inhibitors, Sulfonamides, business.industry, Middle Aged, medicine.disease, Radiation therapy, Radiation Recall Dermatitis, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae431471b2e37a6b631505cdcfaceea6Test
https://pubmed.ncbi.nlm.nih.gov/23699661Test

المؤلفون: Marta Nyakas, Stuart Spencer, Mireille Cantarini, Reinhard Dummer, Gabriella Liszkay, Paul Lorigan, Ana Arance, Caroline Robert, Mark R. Middleton, Dirk Schadendorf, Ralf Gutzmer, Kevin B. Kim

المساهمون: University of Zurich, Robert, Caroline

مصطلحات موضوعية: Male, Skin Neoplasms, Time Factors, medicine.medical_treatment, DNA Mutational Analysis, Medizin, Phases of clinical research, Kaplan-Meier Estimate, Gastroenterology, Antineoplastic Combined Chemotherapy Protocols, Melanoma, 10177 Dermatology Clinic, Middle Aged, Dacarbazine, Europe, Phenotype, Treatment Outcome, Oncology, Tolerability, Female, 2730 Oncology, Brazil, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Neutropenia, Placebo, Disease-Free Survival, Drug Administration Schedule, Double-Blind Method, Internal medicine, medicine, Humans, Genetic Predisposition to Disease, Antineoplastic Agents, Alkylating, Protein Kinase Inhibitors, Aged, Proportional Hazards Models, Chemotherapy, Intention-to-treat analysis, business.industry, medicine.disease, United States, Surgery, Logistic Models, Mutation, Selumetinib, Neoplasms, Unknown Primary, Benzimidazoles, business

وصف الملف: 555_Robert_C_et_al._-_Lancet_Oncol_2013.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c63162f2b90b77be9846693c33b4197Test
https://www.ncbi.nlm.nih.gov/pubmed/23735514Test